Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 48

1.

High-Sensitivity Troponin T and NT-proBNP Kinetics in Breast Cancer Chemotherapy.

Advani P, Hoyne J, Moreno-Aspita A, Dubin M, Brock S, Harlow C, Chumsri S, Suter T, Blackshear JL.

Chemotherapy. 2017 Jul 14;62(6):334-338. doi: 10.1159/000477797. [Epub ahead of print]

PMID:
28704807
2.

The interplay of epigenetic therapy and immunity in locally recurrent or metastatic estrogen receptor-positive breast cancer: Correlative analysis of ENCORE 301, a randomized, placebo-controlled phase II trial of exemestane with or without entinostat.

Tomita Y, Lee MJ, Lee S, Tomita S, Chumsri S, Cruickshank S, Ordentlich P, Trepel JB.

Oncoimmunology. 2016 Aug 31;5(11):e1219008. doi: 10.1080/2162402X.2016.1219008. eCollection 2016.

3.

Patient-reported Adherence to Adjuvant Aromatase Inhibitor Therapy Using the Morisky Medication Adherence Scale: An Evaluation of Predictors.

Kesmodel SB, Goloubeva OG, Rosenblatt PY, Heiss B, Bellavance EC, Chumsri S, Bao T, Thompson J, Nightingale G, Tait NS, Nichols EM, Feigenberg SJ, Tkaczuk KH.

Am J Clin Oncol. 2016 Jun 17. [Epub ahead of print]

PMID:
27322700
4.

Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti-HER2 targeted therapies.

Ross JS, Gay LM, Wang K, Ali SM, Chumsri S, Elvin JA, Bose R, Vergilio JA, Suh J, Yelensky R, Lipson D, Chmielecki J, Waintraub S, Leyland-Jones B, Miller VA, Stephens PJ.

Cancer. 2016 Sep 1;122(17):2654-62. doi: 10.1002/cncr.30102. Epub 2016 Jun 10.

PMID:
27284958
5.

Circulating Cancer-Associated Macrophage-Like Cells Differentiate Malignant Breast Cancer and Benign Breast Conditions.

Adams DL, Adams DK, Alpaugh RK, Cristofanilli M, Martin SS, Chumsri S, Tang CM, Marks JR.

Cancer Epidemiol Biomarkers Prev. 2016 Jul;25(7):1037-42. doi: 10.1158/1055-9965.EPI-15-1221. Epub 2016 May 17.

6.

Mitosis in circulating tumor cells stratifies highly aggressive breast carcinomas.

Adams DL, Adams DK, Stefansson S, Haudenschild C, Martin SS, Charpentier M, Chumsri S, Cristofanilli M, Tang CM, Alpaugh RK.

Breast Cancer Res. 2016 May 4;18(1):44. doi: 10.1186/s13058-016-0706-4.

7.

Dual HER2 blockade in the neoadjuvant and adjuvant treatment of HER2-positive breast cancer.

Advani P, Cornell L, Chumsri S, Moreno-Aspitia A.

Breast Cancer (Dove Med Press). 2015 Sep 22;7:321-35. doi: 10.2147/BCTT.S90627. eCollection 2015. Review.

8.

Prolonged Response to Trastuzumab in a Patient With HER2-Nonamplified Breast Cancer With Elevated HER2 Dimerization Harboring an ERBB2 S310F Mutation.

Chumsri S, Weidler J, Ali S, Balasubramanian S, Wallweber G, DeFazio-Eli L, Chenna A, Huang W, DeRidder A, Goicocheal L, Perez EA.

J Natl Compr Canc Netw. 2015 Sep;13(9):1066-70.

PMID:
26358791
9.

RUNX2 and TAZ-dependent signaling pathways regulate soluble E-Cadherin levels and tumorsphere formation in breast cancer cells.

Brusgard JL, Choe M, Chumsri S, Renoud K, MacKerell AD Jr, Sudol M, Passaniti A.

Oncotarget. 2015 Sep 29;6(29):28132-50. doi: 10.18632/oncotarget.4654.

10.

Histone deacetylase inhibitor entinostat in combination with a retinoid downregulates HER2 and reduces the tumor initiating cell population in aromatase inhibitor-resistant breast cancer.

Schech AJ, Shah P, Yu S, Sabnis GJ, Goloubeva O, Rosenblatt P, Kazi A, Chumsri S, Brodie A.

Breast Cancer Res Treat. 2015 Aug;152(3):499-508. doi: 10.1007/s10549-015-3442-z. Epub 2015 Jul 2.

PMID:
26133921
11.

Clinical utilities of aromatase inhibitors in breast cancer.

Chumsri S.

Int J Womens Health. 2015 May 6;7:493-9. doi: 10.2147/IJWH.S69907. eCollection 2015. Review.

12.

The RUNX2 Transcription Factor Negatively Regulates SIRT6 Expression to Alter Glucose Metabolism in Breast Cancer Cells.

Choe M, Brusgard JL, Chumsri S, Bhandary L, Zhao XF, Lu S, Goloubeva OG, Polster BM, Fiskum GM, Girnun GD, Kim MS, Passaniti A.

J Cell Biochem. 2015 Oct;116(10):2210-26. doi: 10.1002/jcb.25171.

13.

The systematic study of circulating tumor cell isolation using lithographic microfilters.

Adams DL, Zhu P, Makarova OV, Martin SS, Charpentier M, Chumsri S, Li S, Amstutz P, Tang CM.

RSC Adv. 2014;9:4334-4342.

14.

Cytometric characterization of circulating tumor cells captured by microfiltration and their correlation to the CellSearch(®) CTC test.

Adams DL, Stefansson S, Haudenschild C, Martin SS, Charpentier M, Chumsri S, Cristofanilli M, Tang CM, Alpaugh RK.

Cytometry A. 2015 Feb;87(2):137-44. doi: 10.1002/cyto.a.22613. Epub 2014 Dec 16.

15.

Lymphoepithelioma-like carcinoma of the breast presenting as breast abscess.

Suzuki I, Chakkabat P, Goicochea L, Campassi C, Chumsri S.

World J Clin Oncol. 2014 Dec 10;5(5):1107-12. doi: 10.5306/wjco.v5.i5.1107.

16.

Brain metastasis and response to ado-trastuzumab emtansine: a case report and literature review.

Kalsi R, Feigenberg S, Kwok Y, Tkaczuk K, Mehta M, Chumsri S.

Clin Breast Cancer. 2015 Apr;15(2):e163-6. doi: 10.1016/j.clbc.2014.10.003. Epub 2014 Oct 19. Review. No abstract available.

PMID:
25454740
17.

Combined cancer therapy: strategies to overcome acquired aromatase inhibitor resistance.

Kesmodel SB, Sabnis GJ, Chumsri S, Brodie AM.

Curr Pharm Des. 2014;20(42):6575-83. Review.

PMID:
25341934
18.

Chemotherapy dose reduction due to chemotherapy induced peripheral neuropathy in breast cancer patients receiving chemotherapy in the neoadjuvant or adjuvant settings: a single-center experience.

Bhatnagar B, Gilmore S, Goloubeva O, Pelser C, Medeiros M, Chumsri S, Tkaczuk K, Edelman M, Bao T.

Springerplus. 2014 Jul 16;3:366. doi: 10.1186/2193-1801-3-366. eCollection 2014.

19.

Nicotine promotes apoptosis resistance of breast cancer cells and enrichment of side population cells with cancer stem cell-like properties via a signaling cascade involving galectin-3, α9 nicotinic acetylcholine receptor and STAT3.

Guha P, Bandyopadhyaya G, Polumuri SK, Chumsri S, Gade P, Kalvakolanu DV, Ahmed H.

Breast Cancer Res Treat. 2014 May;145(1):5-22. doi: 10.1007/s10549-014-2912-z. Epub 2014 Mar 26.

20.

mTOR inhibitors: changing landscape of endocrine-resistant breast cancer.

Chumsri S, Sabnis G, Tkaczuk K, Brodie A.

Future Oncol. 2014 Feb;10(3):443-56. doi: 10.2217/fon.13.178. Review.

PMID:
24559450

Supplemental Content

Loading ...
Support Center